News | December 31, 2023
Roche to buy LumiraDx’s technology platform for US$ 295 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Expands robotics to 20+ specialities
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
Subscribe To Our Newsletter & Stay Updated
